Impact of combined secondary prevention therapy after myocardial infarction: Data from a nationwide French registry

American Heart Journal

Volumn 150, Issue 6, 2005, Pages 1147-1153

  Danchin, Nicolas ^a   Cambou, Jean Pierre ^b   Hanania, Guy ^c   Kadri, Zena ^a   Genès, Nathalie ^d   Lablanche, Jean Marc ^e   Blanchard, Didier ^f   Vaur, Laurent ^d   Clerson, Pierre ^g   Guéret, Pascal ^h  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSERM   (France)

^c Centre Hospitalier d'Aulnay   (France)

^d SANOFI   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f Clinique Saint Gatien   (France)

^g Orgametrie   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FRANCE; HEART EJECTION FRACTION; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REGISTER; REGRESSION ANALYSIS; RISK ASSESSMENT; SAMPLE SIZE; SCORING SYSTEM; SURVIVAL RATE;

ADRENERGIC BETA-AGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; REGISTRIES; REGRESSION ANALYSIS;

EID: 28844494099     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.01.058     Document Type: Article

References (17)

1. Antithrombotic trialists' collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
2. N. Freemantle, J. Cleland, and P. Young β-Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737
3. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
4. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
5. Heart Protection Study collaborative group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial Lancet 360 2002 7 22
6. P.S. Sever, B. Dahlöf, and N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial Lancet 361 2003 1149 1158
7. The Heart Outcomes Prevention Evaluation Study investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
8. The European trial on reduction of cardiac event with perindopril in stable coronary artery disease investigators Efficacy of perindopril on reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study) Lancet 362 2003 782 788
9. G. Hanania, J.P. Cambou, and P. Guéret Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nation-wide USIC 2000 registry Heart 90 2004 1404 1410
10. The Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
11. M.M. Joffe, and P.R. Rosenbaum Propensity scores Am J Epidemiol 150 1999 327 333
12. N. Danchin, L. Vaur, and N. Genès Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results J Am Coll Cardiol 30 1997 1598 1605
13. N. Danchin, O. Grenier, and J. Ferrières Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey Heart 88 2002 159 162
14. N. Danchin, G. Hanania, and O. Grenier Evolution du traitement de sortie après hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000: donnés des études USIK 1995, Prévenir 1 et 2 et USIC 2000 Ann Cardiol Angéiol 52 2003 1 6
15. N.J. Wald, and M.R. Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419 1424
16. P. Gaede, P. Vedel, and N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes mellitus N Engl J Med 348 2003 383 393
17. D. Mukherjee, J. Fang, and S. Chetcuti Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes Circulation 109 2004 745 749